

LYME DISEASE

is a growing
concern
in Canada

Get powerful,
broad protection
where it's needed.




Nobivac Lyme provides DUAL protection to
kill *Borellia burgdorferi* in the tick AND in the dog.

Nobivac 
Protection unites us.

 **MERCK**
Animal Health


The importance of DUAL protection

OspA is expressed on the surface of *B. burgdorferi* while the bacteria is in the midgut of the tick.



This provides two opportunities to target and kill *B. burgdorferi*.

DUAL borreliacidal protection with Nobivac® Lyme




1 Nobivac® Lyme induces OspA borreliacidal antibodies to kill *B. burgdorferi* that are expressing OspA inside the tick.¹

2 Nobivac® Lyme induces OspC borreliacidal antibodies to kill bacteria that are expressing OspC in the tick AND the dog.^{1,2}


Nobivac® Lyme delivers two powerful lines of defense - in the tick AND in the dog.

The importance of BROAD OspC protection

30 Recognized subtypes of OspC



Anti-OspC Antibodies



“In dogs residing in North America, Lyme borreliosis has only been associated with *B. burgdorferi sensu stricto* (*Bb*), of which at least 30 subtypes or strains exist, based on outer surface protein C or OspC genotyping.”

ACVIM consensus update on Lyme borreliosis in dogs and cats³

Nobivac Lyme is the only vaccine shown to stimulate antibodies to a conserved region of OspC, common to all 30 recognized subtypes, delivering broad protection.¹

Nobivac[®] Lyme delivers a broad second line of defense.

The Nobivac[®] PRICE DIFFERENCE⁴

Nobivac [®] Lyme	Vaccine R	Vaccine V
per dose	per dose	per dose
\$15.80	\$19.00 ⬆️ \$3.20	\$20.55 ⬆️ \$4.75
Stimulates OspA antibodies. ¹	Stimulates OspA antibodies.	Stimulates OspA antibodies.
Stimulates broad OspC borreliacidal protection. ¹	No stimulation of OspC borreliacidal antibody production demonstrated.	Provides antigenic material from 7 common subtypes of OspC.



Nobivac 
Protection unites us.

Provide Pet Parents with the information they need

DOG OWNERS recently surveyed⁵


48%

are concerned or very concerned about the risk of Lyme disease transmission to their dogs.


15%

have not had their dog vaccinated but are likely or very likely to do so.

Resources for your practice when you purchase Nobivac® Lyme



NOBIVAC® LYME EXPLAINER VIDEO



POSTERS



BROCHURES



With every **NOBIVAC® VACCINE** you give patients in your clinic, you help support the **AFYA program**. This program is committed to the global effort of eliminating dog-mediated rabies in humans by 2030.

5 MILLION
DOSES
DONATED

25 YEARS
OF
COMMITMENT

HELPING ELIMINATE RABIES BY 2030

COLLABORATE. VACCINATE.

LEARN MORE



1. LaFleur RL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. *Clin Vaccine Immunol* 2009; 16(2):253-9.
 2. LaFleur RL, et al. Vaccination with the ospA- and ospB-Negative *Borrelia burgdorferi* Strain 50772 Provides Significant Protection against Canine Lyme. *Clin Vaccine Immunol* 2015; 22(7):836-9.
 3. Littman MP, et al. ACVIM consensus update on Lyme borreliosis in dogs and cats. *J Vet Intern Med.* 2018 May;32(3):887-903
 4. Prices listed at buying groups, December 2022.
 5. Canadian dog owner market research, Guilbault Marketing. July, 2019.
 NOBIVAC® is a registered trademark of Intervet International B.V. Used under license.
 MERCK® is a registered trademark of Merck Sharp & Dohme LLC. Used under license.
 Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. CA-NOV-221200003